Text size: A A A

The impact and risks of vitreomacular traction (VMT) and macular hole

As you see in your patients, vitreomacular traction (VMT) and macular hole
often result in visual impairment, particularly central vision loss5-9

Key symptoms include metamorphopsia, visual field defects,
and vision loss5,10,11

Key symptoms include metamorphopsia, visual field defects, and vision loss5,10,11

Normal vision12 Metamorphopsia*12 Central vision defect*12


Tap to view respective OCT scans.

The impact on visual function of vitreomacular traction (VMT) and macular hole can affect activities of daily living and quality of life16,17

Patients may experience:

  • Compromised sight-related activities
  • Physical constraints
  • Emotional impact

Patients with vitreomacular traction (VMT) have been shown to experience comorbid eye conditions10,14

While vitreomacular traction (VMT) can resolve spontaneously, patients with this condition are at risk for macular hole, and early stage macular holes have been shown to progress to more advanced stages.10,18 In addition, patients with vitreomacular traction (VMT) may have eye diseases such as exudative age-related macular degeneration (AMD) and diabetic macular edema.19,20

VMT OCT scan12
VMT OCT scan12
Vitreomacular (VMT) OCT scan
  • Only around 10% of patients with vitreomacular traction (VMT) resolve spontaneously14
Macular hole OCT scan12
Macular hole OCT scan12
Macular hole OCT scan
  • About 75% of Stage 2 macular holes progress with an increase in hole size18,21
  • Only 3% to 11% of patients experience spontaneous closure of full-thickness macular hole18,22-24

Next: Diagnosis and Treatment

Take action with JETREA® (ocriplasmin) Intravitreal (IVT) Injection

JETREA® Cross eye JETREA® Cross eye JETREA® Cross eye

A one-time injection of JETREA® has been shown to provide early resolution of vitreomacular traction, including when associated with macular hole of diameter ≤400 µm.1


See the JETREA® difference in your practice with the Impact Calculator™

Impact Calculator® Impact Calculator® Impact Calculator®

Calculate how many patients with vitreomacular traction you can potentially treat in 1 year with the one-time injection of JETREA®.1


Compare the anatomical evidence of JETREA®

Vitreomacular (VMT) OCT scan at Day 28 Vitreomacular (VMT) OCT scan at Day 28 Vitreomacular (VMT) OCT scan at Day 28

Landmark studies provide anatomical evidence for early pharmacologic resolution of vitreomacular traction.1,2,12


Important Safety Information

Indications: JETREA® is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

Dosage: JETREA® must be prepared and administered by a qualified ophthalmologist experienced in intravitreal injections. The recommended dose is 0.125 mg (0.1 mL of the diluted solution) administered by intravitreal injection to the affected eye once as a single dose.

Contraindications: JETREA® is contraindicated for use with patients who are hypersensitive to ocriplasmin or to any of the excipients in JETREA® (mannitol, citric acid, sodium hydroxide and water), or with patients who have active or suspected ocular or periocular infections.

Warnings and Precautions: Post-Injection Monitoring: Intravitreal injections have been associated with intraocular inflammation/infection, intraocular haemorrhage and increased intraocular pressure (IOP). Proper aseptic injection techniques must always be used. Following the intravitreal injection, patients should be monitored for any side effects such as (but not limited to) intraocular inflammation/infection and elevation in IOP. Other Warnings and Precautions: Administration of JETREA® to both eyes concurrently has not been studied, and is not recommended. Repeated administration of JETREA® in the same eye has not been studied, and is not recommended. There are no clinical data on the concomitant use of ocriplasmin with VEGF-inhibitors. JETREA® has not been studied in patients with large diameter macular holes (>400 microns), high myopia (>8 dioptre spherical correction or axial length >28 mm), aphakia, history of rhegmatogenous retinal detachment, lens zonule instability, recent ocular surgery or intraocular injection (including laser therapy), proliferative diabetic retinopathy, ischaemic retinopathies, retinal vein occlusions, exudative age-related macular degeneration (AMD) and vitreous haemorrhage; treatment is not recommended in these patients. The potential for lens subluxation or phacodonesis cannot be ruled out. There is limited experience in patients with non-proliferative diabetic retinopathy or in patients with a history of uveitis or significant eye trauma; caution should be exercised when treating such patients. The effect of ocriplasmin (particularly in inducing resolution of vitreomacular adhesion (VMA) or causing total posterior vitreous detachment (PVD) is reduced in subjects with an epiretinal membrane (ERM) or a diameter of VMA >1500 microns. Due to a potential increase in tractional forces, there is a risk of occurrence of new or enlarged macular holes. There is a risk for a significant, but transient loss of visual acuity during the first week after the injection; patients should be monitored appropriately.

Interactions: No formal interaction studies have been conducted.

Undesirable Effects: In the JETREA® clinical studies, all adverse reactions were ocular. Most of the adverse reactions occurred within the first week after the injection. The majority of these reactions were non-serious, mild in intensity and resolved within 2 to 3 weeks. The incidence of serious adverse reactions that occurred in all clinical studies was 2.2% in JETREA® treated patients and 2.4% in placebo-controlled patients. Very common (≥1/10) adverse reactions are: vitreous floaters, eye pain, and conjunctival haemorrhage. Common (≥1/100 to <1/10) adverse reactions are: visual acuity reduced, visual impairment, vision blurred, retinal haemorrhage, vitreous haemorrhage, retinal tear, retinal detachment, intraocular pressure increased,macular hole, macular degeneration, retinal degeneration, macular oedema, retinal oedema, retinal pigment epitheliopathy, metamorphopsia, vitreous adhesions, conjunctival oedema, eyelid oedema, vitritis, anterior chamber cell, anterior chamber flare, iritis, photopsia, conjunctival hyperaemia, ocular hyperaemia, vitreous detachment, retinogram abnormal, eye irritation, dry eye, foreign body sensation in eyes, eye pruritus, ocular discomfort, photophobia, and chromatopsia. Uncommon (≥1/1,000 to <1/100) are: transient blindness, lens subluxation, scotoma, visual field defect, diplopia, hyphaema, miosis, pupils unequal, corneal abrasion, anterior chamber inflammation, eye inflammation, and conjunctival irritation.

Click here to review the JETREA® Summary of Product Characteristics.